Inozyme Pharma Ownership | Who Owns Inozyme Pharma?
Inozyme Pharma Ownership Summary
Inozyme Pharma is owned by 86.25% institutional investors, 0.51% insiders, and 13.24% retail investors. Adage capital partners gp is the largest institutional shareholder, holding 9.27% of INZY shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 5.87% of its assets in Inozyme Pharma shares.
INZY Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Inozyme Pharma | 86.25% | 0.51% | 13.24% |
| Sector | Healthcare Stocks | 47.06% | 8.01% | 44.93% |
| Industry | Biotech Stocks | 44.97% | 7.82% | 47.21% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Adage capital partners gp | 5.73M | 9.27% | $25.55M |
| Pivotal bioventure partners investment advisor | 4.49M | 7.28% | $20.05M |
| Sofinnova investments | 4.28M | 6.93% | $19.09M |
| Eventide asset management | 3.94M | 6.37% | $17.56M |
| Rock springs capital management lp | 3.70M | 5.99% | $16.49M |
| Samlyn capital | 3.35M | 5.42% | $14.94M |
| Blackrock | 3.34M | 5.41% | $14.91M |
| Affinity asset advisors | 2.86M | 4.62% | $12.74M |
| Vanguard group | 2.63M | 4.26% | $11.73M |
| Fmr | 2.48M | 4.01% | $11.05M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Pivotal bioventure partners investment advisor | 4.49M | 15.41% | $20.05M |
| Saturn v capital management | 1.14M | 1.92% | $5.09M |
| Affinity asset advisors | 2.86M | 1.47% | $12.74M |
| Samsara biocapital | 1.56M | 1.46% | $6.97M |
| Blue owl capital lp | 1.12M | 1.39% | $5.00M |
| Knott david m jr | 564.55K | 1.00% | $2.52M |
| Sofinnova investments | 4.28M | 0.99% | $19.09M |
| Sphera funds management | 1.46M | 0.89% | $6.52M |
| Nea management company | 2.44M | 0.82% | $10.87M |
| Rock springs capital management lp | 3.70M | 0.50% | $16.49M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Saturn v capital management | 1.14M | 1.92% | 1.14M |
| Millennium management | 1.79M | 0.00% | 1.08M |
| Eventide asset management | 3.94M | 0.30% | 756.38K |
| Fmr | 2.48M | 0.00% | 510.00K |
| Samlyn capital | 3.35M | 0.25% | 437.62K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Kennedy capital management | - | - | -437.66K |
| Exome asset management | - | - | -273.41K |
| Parkman healthcare partners | - | - | -222.94K |
| Blue owl capital lp | 1.12M | 1.39% | -150.00K |
| Laurion capital management lp | - | - | -126.54K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Saturn v capital management | 1.14M | 1.92% | 1.14M | $5.09M |
| Exoduspoint capital management, lp | 55.19K | 0.00% | 55.19K | $246.00K |
| Pale fire capital se | 38.90K | 0.02% | 38.90K | $173.50K |
| Corebridge financial | 27.81K | 0.00% | 27.81K | $124.04K |
| Mirae asset global etfs | 24.41K | 0.00% | 24.41K | $108.85K |
Sold Out
| Holder | Change |
|---|---|
| Nelson, van denburg & campbell wealth management group | -9.00 |
| Rothschild investment | -25.00 |
| Ica group wealth management | -85.00 |
| Signaturefd | -113.00 |
| Entrypoint capital | -1.46K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2024 | 89 | -3.26% | 54,577,497 | 1.39% | 86 | 1.14% | 44 | -22.81% | 22 | 15.79% |
| Jun 30, 2024 | 91 | - | 53,828,169 | 7.93% | 87 | 0.94% | 57 | 39.02% | 18 | -41.94% |
| Mar 31, 2024 | 91 | 9.64% | 49,874,140 | -0.33% | 96 | 1.24% | 41 | -22.64% | 31 | 106.67% |
| Dec 31, 2023 | 83 | 2.47% | 50,036,907 | 2.76% | 88 | 0.75% | 53 | 20.45% | 15 | -25.00% |
| Sep 30, 2023 | 81 | 6.58% | 48,693,887 | 42.67% | 108 | 1.78% | 44 | -22.81% | 20 | 81.82% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Eventide Healthcare & Life Sciences I | 3.94M | 5.87% | 756.38K |
| Fidelity Select Biotechnology | 2.47M | 3.68% | - |
| Vanguard Total Stock Mkt Idx Inv | 1.56M | 2.43% | - |
| iShares Russell 2000 ETF | 1.33M | 2.07% | -3.00K |
| Vanguard Institutional Extnd Mkt Idx Tr | 679.65K | 1.01% | - |
| Fidelity Small Cap Index | 527.75K | 0.79% | -12.64K |
| iShares Russell 2000 Value ETF | 484.29K | 0.75% | - |
| State St Russell Sm/Mid Cp® Indx NL Cl C | 322.90K | 0.50% | -10.60K |
| Fidelity Extended Market Index | 278.58K | 0.42% | 10.01K |
| Vanguard Russell 2000 ETF | 235.32K | 0.37% | -1.46K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Apr 02, 2024 | Treco Douglas A | CEO | Sell | $52.21K |
| Aug 01, 2023 | Pivotal bioVenture Partners Fund I, L.P. | - | Buy | $3.43M |
| Aug 01, 2023 | Pivotal bioVenture Partners Fund I, L.P. | - | Buy | $571.43K |
| Aug 01, 2023 | Hopfner Robert Lorne | - | Buy | $3.43M |
| Aug 01, 2023 | Hopfner Robert Lorne | - | Buy | $571.43K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2024 Q2 | - | 1 |
| 2024 Q1 | - | - |
| 2023 Q3 | 4 | - |
| 2023 Q2 | 2 | - |
| 2023 Q1 | 3 | - |
INZY Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools